 Patients undergo blood, urine, and tissue sample collection for pharmacogenomic, pharmacokinetic, and biomarker laboratory studies. Blood and urine samples are collected at baseline, after 1 week of treatment, and at the time of surgery for pharmacokinetic and urine biomarker survivin and BLCA-4 studies. Pharmacogenomic studies epidermal growth factor receptor EGFR polymorphisms and CYP3A 45 genotypes are performed at baseline using blood samples. Tissue biomarker EGFR polymorphism, EGFR mutations EGFR vIII, exon 19-21, EGFR, phosphorylated EGFR, Ki67, activated caspase 3, Akt, P-Akt, MAP kinase, P-MAP kinase, COX-2, survivin, and BLCA4 studies using tumor tissue and adjacent and remote normal urothelium are performed at baseline and at the completion of treatment. 